ストックスクリーナーアプリを入手
4.923
1.20%
0.053
Atea Pharmaceuticals Inc (AVIR) 最新ニュース
AVIRAtea Pharmaceuticals Inc Short Interest - Finviz
Atea Pharmaceuticals (AVIR) Q1 2026 Earnings: Beat on EPS Despite Pre-Revenue Status; Stock Climbs 2.67%Consensus Forecast Report - dars.gov.et
Price to earnings forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to book forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to sales forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – NASDAQ:AVIR - TradingView
Price to earnings forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to EBITDA forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Enterprise value to revenue forward of Atea Pharmaceuticals, Inc. – BOATS:AVIR - TradingView
Atea Pharmaceuticals Inc (AVIR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Down 25% in 4 weeks, here's why Atea Pharmaceuticals (AVIR) looks ripe for a turnaround - MSN
AVIR SEC FilingsAtea Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Atea Pharmaceuticals (NASDAQ:AVIR) Refocuses Antiviral Pipeline - Kalkine Media
Atea Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:AVIR) - TradingView
Atea Pharmaceuticals Inc (AVIR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AVIR Forecast — Price Target — Prediction for 2027 - TradingView
Atea completes enrollment in phase 3 hepatitis C trial By Investing.com - Investing.com Australia
Atea completes enrollment in phase 3 hepatitis C trial - Investing.com UK
Atea Pharmaceuticals Completes Patient Enrollment in Phase - GlobeNewswire
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - Sahm
Form 4 Atea Pharmaceuticals Inc For: 23 June By Investing.com - Investing.com Nigeria
Atea (NASDAQ: AVIR) grants Bruno Lucidi options and new RSUs - Stock Titan
[Form 4] Atea Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Equity awards boost Atea (AVIR) director Barbara Duncan’s holdings - Stock Titan
Director Howard Berman receives new equity awards at Atea (NASDAQ: AVIR) - Stock Titan
Atea Pharmaceuticals (AVIR) director receives new options and RSU awards - Stock Titan
Atea Pharmaceuticals (AVIR) director reports RSU vesting and new option grant - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) director reports RSU exercise and new option, RSU grants - Stock Titan
Atea Pharmaceuticals (NASDAQ: AVIR) grants options and RSUs to director - Stock Titan
Atea Pharmaceuticals elects directors and approves proposals at annual meeting - Investing.com Nigeria
Atea Shareholders Back Directors, Auditors and Executive Pay - TipRanks
Form 8K Atea Pharmaceuticals Inc For: 22 June By Investing.com - Investing.com South Africa
Atea Pharmaceuticals (NASDAQ: AVIR) reports 2026 annual meeting and vote outcomes - Stock Titan
Atea Pharmaceuticals (AVIR) upgraded to buy: Here's what you should know - MSN
Atea Pharmaceuticals (AVIR) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Atea Pharmaceuticals (AVIR) AGM 2026 Summary - Quartr
Atea Pharmaceuticals Inc (AVIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Atea Pharmaceuticals Inc (AVIR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Atea Pharmaceuticals Inc (AVIR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Atea Pharmaceuticals Inc (AVIR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Atea Pharmaceuticals Inc (AVIR) Institutional Confidence - TradingKey
Atea Pharmaceuticals Inc (AVIR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Atea Pharmaceuticals (AVIR) price target increased by 33.33% to 8.16 - MSN
Atea Pharmaceuticals (AVIR) Slides 3.79%: Testing Key Support Near $4.10 Amid Ongoing VolatilitySchiff Line - dars.gov.et
Are medical stocks lagging Atea Pharmaceuticals (AVIR) this year? - MSN
Are Medical Stocks Lagging Atea Pharmaceuticals (AVIR) This Year? - Yahoo Finance
1.53%
3.59%
大文字化:
|
ボリューム (24 時間):